Transmedics Group Inc
Change company Symbol lookup
Select an option...
TMDX Transmedics Group Inc
CBLUY China BlueChemical Ltd
NIO NIO Inc
MSFT Microsoft Corp
LMT Lockheed Martin Corp
DD Dupont De Nemours Inc
DOW Dow Inc
CTVA Corteva Inc
CSCO Cisco Systems Inc
AAPL Apple Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Heart EXPAND Trial, OCS Heart EXPAND Continued Access Protocol, or CAP, Trial and OCS Heart PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile.

Postmarket

Last Trade
Delayed
$27.03
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$27.03
Day's Change
-0.41 (-1.49%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
27.75
Day's Low
26.77
Volume
(Light)
Volume:
130,060

10-day average volume:
188,584
130,060

Company Profile

Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Heart EXPAND Trial, OCS Heart EXPAND Continued Access Protocol, or CAP, Trial and OCS Heart PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
25.36x
Price/Book (MRQ)
8.53x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2021
Current Month
936.9K
Previous Month
1.0M
Percent of Float
3.64%
Days to Cover
5.0671 Days

Share Information

TMDX is in a share class of common stock
Float
25.7M
Shares Outstanding
27.7M
Institutions Holding Shares
162
70.03%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • James R. Tobin
  • Waleed H. HassaneinPres.
  • Stephen GordonCFO
  • John F. Carey
  • Laura DammeVP

Address

  • 200 Minuteman Road
  • Andover, MA 01810
  • Phone: (978) 552-0900

Insider Trading

During the most recent quarter, 57K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.